Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 865-871

  Woolthuis, Carolien M ^a   Mariani, Niccoló ^a,b   Verkaik Schakel, Rikst Nynke ^a   Brouwers Vos, Annet Z ^a   Schuringa, Jan Jacob ^a   Vellenga, Edo ^a   de Wolf, Joost T M ^a   Huls, Gerwin ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Autologous stem cell transplantation; Hematopoietic progenitor cell; Hematopoietic stem cell

Indexed keywords

CD34 ANTIGEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; AGING; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; CELL FUNCTION; CELL LINEAGE; CELL REGENERATION; CELL STRESS; COMPARATIVE STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; STEM CELL MOBILIZATION; AGE; AUTOTRANSPLANTATION; BONE MARROW CELL; COHORT ANALYSIS; CYTOLOGY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; PHYSIOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; AGE FACTORS; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; COHORT STUDIES; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84899969010     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.001     Document Type: Article

References (45)

1. Deschler B., Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006, 107:2099-2107.
2. Lichtman M.A., Rowe J.M. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol 2004, 31:185-197.
3. de Jonge H.J., de Bont E.S., Valk P.J., et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 2009, 114:2869-2877.
4. Gruver A.L., Hudson L.L., Sempowski G.D. Immunosenescence of ageing. J Pathol 2007, 211:144-156.
5. Hakim F.T., Gress R.E. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens 2007, 70:179-189.
6. Linton P.J., Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004, 5:133-139.
7. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2263-2268.
8. Izaks G.J., Westendorp R.G., Knook D.L. The definition of anemia in older persons. JAMA 1999, 281:1714-1717.
9. Kim M., Moon H.B., Spangrude G.J. Major age-related changes of mouse hematopoietic stem/progenitor cells. Ann NY Acad Sci 2003, 996:195-208.
10. Rossi D.J., Bryder D., Zahn J.M., et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA 2005, 102:9194-9199.
11. Sudo K., Ema H., Morita Y., Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. J Exp Med 2000, 192:1273-1280.
12. Chambers S.M., Shaw C.A., Gatza C., et al. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol 2007, 5:e201.
13. de Haan G., Nijhof W., Van Zant G. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood 1997, 89:1543-1550.
14. Morrison S.J., Wandycz A.M., Akashi K., et al. The aging of hematopoietic stem cells. Nat Med 1996, 2:1011-1016.
15. Kuranda K., Vargaftig J., de la Rochere P., et al. Age-related changes in human hematopoietic stem/progenitor cells. Aging Cell 2011, 10:542-546.
16. Pang W.W., Price E.A., Sahoo D., et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA 2011, 108:20012-20017.
17. Schepers H., van Gosliga D., Wierenga A.T., et al. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007, 110:2880-2888.
18. Lokhorst H.M., Schmidt-Wolf I., Sonneveld P., et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008, 93:124-127.
19. Segeren C.M., Sonneveld P., van der Holt B., et al. Vincristine, doxorubicin, and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999, 105:127-130.
20. Lokhorst H.M., van der Holt B., Zweegman S., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
21. + NHL: a prospective randomized HOVON trial. Blood 2008, 111:537-543.
22. Beerman I., Maloney W.J., Weissmann I.L., Rossi D.J. Stem cells and the aging hematopoietic system. Curr Opin Immunol 2010, 22:500-506.
23. + cells. Scand J Clin Lab Invest 2009, 69:79-84.
24. Muschler G.F., Nitto H., Boehm C.A., Easley K.A. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001, 19:117-125.
25. Ogawa T., Kitagawa M., Hirokawa K. Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages. Mech Ageing Dev 2000, 117:57-68.
26. Nieboer P., de Vries E.G., Vellenga E., et al. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies: 1-year analysis. Eur J Cancer 2004, 40:1199-1207.
27. Woolthuis C., Agool A., Olthof S., et al. Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning. Bone Marrow Transplant 2011, 46:110-115.
28. Woolthuis C.M., Brouwers-Vos A.Z., Huls G., et al. Loss of quiescence and impaired function of CD34(+)/CD38(low) cells one year following autologous stem cell transplantation. Haematologica 2013, 98:1964-1971.
29. Brice P., Marolleau J.P., Pautier P., et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leuk Lymphoma 1996, 22:449-456.
30. Siena S., Bregni M., Di Nicola M., et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994, 5:935-941.
31. Jantunen E., Canals C., Rambaldi A., et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008, 93:1837-1842.
32. Reece D.E., Bredeson C., Perez W.S., et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age. Bone Marrow Transplant 2003, 32:1135-1143.
33. Cottler-Fox M., Lapidot T. Mobilizing the older patient with myeloma. Blood Rev 2006, 20:43-50.
34. Ikeda K., Kozuka T., Harada M. Factors for PBPC collection efficiency and collection predictors. Transfus Apher Sci 2004, 31:245-259.
35. Tempescul A., Ianotto J.C., Hardy E., et al. Peripheral blood stem cell collection in elderly patients. Ann Hematol 2010, 89:317-321.
36. Xing Z., Ryan M.A., Daria D., et al. Increased hematopoietic stem cell mobilization in aged mice. Blood 2006, 108:2190-2197.
37. Liang Y., Van Zant G., Szilvassy S.J. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 2005, 106:1479-1487.
38. Kohler A., Schmithorst V., Filippi M.D., et al. Altered cellular dynamics and endosteal location of aged early hematopoietic progenitor cells revealed by time-lapse intravital imaging in long bones. Blood 2009, 114:290-298.
39. Woolthuis C.M., de Haan G., Huls G. Aging of hematopoietic stem cells: intrinsic changes or micro-environmental effects?. Curr Opin Immunol 2011, 23:512-517.
40. Awaya N., Baerlocher G.M., Manley T.J., et al. Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure?. Biol Blood Marrow Transplant 2002, 8:597-600.
41. Widmann T., Kneer H., Konig J., et al. Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation. Exp Hematol 2008, 36:104-110.
42. Bhatia R., Van H.K., Palmer A., et al. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 2005, 23:6699-6711.
43. Roelofs H., de Pauw E.S., Zwinderman A.H., et al. Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation. Blood 2003, 101:358-362.
44. Rufer N., Brummendorf T.H., Chapuis B., et al. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood 2001, 97:575-577.
45. Wynn R.F., Cross M.A., Hatton C., et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998, 351:178-181.